Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease
Cardiorenal Medicine · 2020 · 10 (1) · 32-41
DOI: 10.1159/000503223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiorenal Medicine, online erschienen am 30.10.2019. Verfasst von Thomas A Mavrakanas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Québec, Canada, thomas.mavrakanas@mail.mcgill.ca. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Introduction
The effect of mineralocorticoid receptor antagonists (MRAs) on chronic kidney disease (CKD) progression in patients with heart failure (HF) and with or without preexisting CKD has not been adequately studied.
Methods
We conducted a retrospective cohort study including consecutive adult patients followed at the HF clinic of a tertiary care center who had already been on an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB). Exposure to MRAs was assessed at 6 months from registration. Patients who were never exposed to an MRA were the control group.
Results
A total of 314 patients who were prescribed an MRA were compared to 1,116 patients who never received an MRA. Among them, 121 and 408 patients, respectively, had CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2). MRAs had to be discontinued in 36/121 patients with CKD (29.8%) and 57/165 patients without CKD (34.5%) (p = 0.39). MRA treatment was associated with a higher risk for persistent creatinine doubling among patients without CKD (hazard ratio 4.07, 95% confidence interval 1.41–11.73). A numerically lower risk was identified among CKD patients (hazard ratio 0.33, 95% confidence interval 0.04–2.78) (p for interaction = 0.009). The primary safety outcome, a composite of any doubling of serum creatinine or any episode of serious hyperkalemia (K+ >6 mmol/L), occurred more commonly in MRA users compared with nonusers in the subgroup of patients without CKD, but not in CKD patients (p for interaction = 0.02).
Conclusion
MRA treatment in addition to an ACEI or an ARB could be safely prescribed in HF patients with CKD as it is not associated with persistent renal function decline, acute kidney injury, or serious hyperkalemia, compared with ACEI/ARB monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Divisions of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Québec, Canada, thomas.mavrakanas@mail.mcgill.ca.
- Department of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, thomas.mavrakanas@mail.mcgill.ca.
- Division of Cardiology, Department of Medicine, McGill University Health Centre, Montreal, Québec, Canada.
- Divisions of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Québec, Canada.
Zitieren
APA
Mavrakanas, T. A., Giannetti, N., Sapir-Pichhadze, R., & Alam, A. (2020). Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease. Cardiorenal Medicine, 10(1), 32-41. https://doi.org/10.1159/000503223
Vancouver
Mavrakanas TA, Giannetti N, Sapir-Pichhadze R, Alam A. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease. Cardiorenal Medicine. 2020;10(1):32-41. doi:10.1159/000503223
BibTeX
@article{Mavrakanas2020,
author = {Mavrakanas, Thomas A and Giannetti, Nadia and Sapir-Pichhadze, Ruth and Alam, Ahsan},
title = {Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease},
journal = {Cardiorenal Medicine},
year = {2020},
volume = {10},
number = {1},
pages = {32--41},
doi = {10.1159/000503223}
}
EUVIMED